At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 363 enrolled
Drug / intervention
Meningococcal vaccine GSK134612 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 When Co-administered With GSK Biologicals' Pneumococcal Vaccine GSK1024850A in Healthy 12-23-month-old Children Previously Primed With GSK1024850A
In Brief
A Phase 3 clinical trial evaluating Meningococcal vaccine GSK134612 and Pneumococcal vaccine GSK1024850A for Infections, Meningococcal. Completed, enrolled 363 participants across 5 sites in 2 countries.
Detailed Summary
The purpose of this study is to demonstrate, in 12-23 months old subjects, the non-inferiority of meningococcal vaccine GSK134612 and pneumococcal vaccine GSK1024850A when co-administered, compared to each vaccine administered individually.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Meningococcal
CountriesMexico, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2008
Enrollment StartOct 2008
Primary CompletionJun 2009
Study CompletionNov 2009
TodayJul 2026
First PostedSep 25, 2008
Enrollment StartOct 30, 2008
Primary CompletionJun 2, 2009
Study CompletionNov 2, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.8 years ago
Interventions
Meningococcal vaccine GSK134612biological
Single dose intramuscular injection.
Pneumococcal vaccine GSK1024850Abiological
Single dose intramuscular injection.